Randomized Phase II Study of Epigenetic Priming Using Decitabine with Induction Chemotherapy in Patients with Acute Myelogenous Leukemia (AML)

The specific purpose of the study is to find out whether decitabine given as an infusion along with induction chemotherapy is safe and effective as a treatment for AML.
There are two treatments to be tested in this study. You may be enrolled to receive decitabine as a 1 hour daily infusion (given into a vein) for 5 days, or to receive decitabine as a 24 hour continuous infusion (given into vein) over 5 days. Both treatments will be given along with induction chemotherapy (a treatment including cytarabine and daunorubicin usually given to patient with AML). You will be in the hospital during and after your treatment. Your study doctor will tell you which dose group you will be participating in prior to your enrollment.

Study Number: 

I 201711

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.